GENFLEET-B (02595) to Present Preclinical Data for Three RAS Pathway Targeted Therapies at 2026 AACR Annual Meeting

Stock News03-20 21:38

GENFLEET-B (02595) announced that it will present preclinical research data for three product candidates during the poster session at the 2026 AACR Annual Meeting. The products are GFH276 (a non-degradative molecular glue), GFS784 (a novel conjugate drug linking a functional antibody with a mechanistically synergistic targeted payload), and GFH603 (a molecular glue-like covalent allosteric activator). The company's RAS therapy portfolio focuses on various selective and pan-RAS inhibitors and continues to investigate potential targets of important co-mutations within the RAS pathway. This portfolio includes diverse molecular formats and multi-mechanism RAS pathway-related large and small molecule targeted drugs. The AACR Annual Meeting will be held from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be presented on April 19 and April 21 respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114020244?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114020244","market":"nz","top_or_hot":-1,"title":"GENFLEET-B (02595) to Present Preclinical Data for Three RAS Pathway Targeted Therapies at 2026 AACR Annual Meeting","media":"Stock News","content":"<p>GENFLEET-B (02595) announced that it will present preclinical research data for three product candidates during the poster session at the 2026 AACR Annual Meeting. The products are GFH276 (a non-degradative molecular glue), GFS784 (a novel conjugate drug linking a functional antibody with a mechanistically synergistic targeted payload), and GFH603 (a molecular glue-like covalent allosteric activator). The company's RAS therapy portfolio focuses on various selective and pan-RAS inhibitors and continues to investigate potential targets of important co-mutations within the RAS pathway. This portfolio includes diverse molecular formats and multi-mechanism RAS pathway-related large and small molecule targeted drugs. The AACR Annual Meeting will be held from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be presented on April 19 and April 21 respectively.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENFLEET-B (02595) to Present Preclinical Data for Three RAS Pathway Targeted Therapies at 2026 AACR Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENFLEET-B (02595) to Present Preclinical Data for Three RAS Pathway Targeted Therapies at 2026 AACR Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-20 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENFLEET-B (02595) announced that it will present preclinical research data for three product candidates during the poster session at the 2026 AACR Annual Meeting. The products are GFH276 (a non-degradative molecular glue), GFS784 (a novel conjugate drug linking a functional antibody with a mechanistically synergistic targeted payload), and GFH603 (a molecular glue-like covalent allosteric activator). The company's RAS therapy portfolio focuses on various selective and pan-RAS inhibitors and continues to investigate potential targets of important co-mutations within the RAS pathway. This portfolio includes diverse molecular formats and multi-mechanism RAS pathway-related large and small molecule targeted drugs. The AACR Annual Meeting will be held from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be presented on April 19 and April 21 respectively.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1114020244","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114020244","pubTimestamp":1774013908,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GENFLEET-B (02595) announced that it will present preclinical research data for three product candidates during the poster session at the 2026 AACR Annual Meeting. The products are GFH276 (a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1515":"抗疫概念","BK1161":"生物科技","02595":"劲方医药-B","BK1574":"生物医药B类股","09939":"开拓药业-B"},"translate_title":"GENFLEET-B（02595）将在2026年AACR年会上展示三种RAS通路靶向疗法的临床前数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"02595":1,"09939":1},"content_text":"GENFLEET-B (02595) announced that it will present preclinical research data for three product candidates during the poster session at the 2026 AACR Annual Meeting. The products are GFH276 (a non-degradative molecular glue), GFS784 (a novel conjugate drug linking a functional antibody with a mechanistically synergistic targeted payload), and GFH603 (a molecular glue-like covalent allosteric activator). The company's RAS therapy portfolio focuses on various selective and pan-RAS inhibitors and continues to investigate potential targets of important co-mutations within the RAS pathway. This portfolio includes diverse molecular formats and multi-mechanism RAS pathway-related large and small molecule targeted drugs. The AACR Annual Meeting will be held from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be presented on April 19 and April 21 respectively.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114020244","isCrawlerRequest":true}